Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00524121 · ClinicalTrials.gov registry record · Phase 2
Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00524121 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 22 participants.
The verdict
NCT00524121, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving erlotinib together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with radiation therapy works in treating older patients with stage I, stage II, stage III, or stage IV esophageal cancer.
Interventions
- OTHER immunohistochemistry staining method
- RADIATION radiation therapy
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-03 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00524121
The ClinicalTrials.gov registry entry for NCT00524121 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which immunohistochemistry staining method is the first listed.
NCT00524121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00524121 about?
NCT00524121 is a clinical study titled "Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving erlotinib together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how wel...
What is the current status of trial NCT00524121?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2006-03. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00524121?
The interventions under investigation include: immunohistochemistry staining method (OTHER), radiation therapy (RADIATION), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00524121?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.